Clinical trial
Effect of Xolair on Airway Hyperresponsiveness
NCT00208234 · Creighton University, Other · Unknown status
Key facts
| NCT number | NCT00208234 |
|---|---|
| Title | Effect of Xolair on Airway Hyperresponsiveness |
| Official title | The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness |
| Lead sponsor | Creighton University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Allergic Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab, Placebo for Omalizumab, omalizumab |
| Enrollment | 22 |
| Start date | Jan 1, 2004 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 23, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: